PLEASANTON, Calif., Dec. 7, 2023
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in
single cell and spatial biology, announced today a collaboration
with the NIH Intramural Center for Alzheimer's and Related
Dementias (NIH CARD) to build a more comprehensive single cell
atlas of the human brain to further neuroscience research. Known
for complementing a broad range of NIH-funded research that
requires harnessing emerging technologies at scale, NIH CARD will
use Chromium Single Cell Multiome to profile the epigenome and
whole transcriptome across millions of individual cells from
ancestrally diverse brain samples.
"Our goal is to provide researchers with a highly detailed
genetic map of the damage caused in neurodegenerative disorders,"
said Andrew B. Singleton, Ph.D., NIH
CARD director. "The hope is that these maps will help scientists
increase their understanding and ultimately develop new and better
treatments for these devastating disorders."
Researchers will analyze more than 1,000 samples across multiple
control and diseased human brain regions — such as the brainstem,
hippocampus, striatum and cerebellum — to learn more about the
cellular changes and underlying regulatory elements associated with
neurodegenerative diseases. NIH CARD scientists aim to produce
high-quality, standardized and harmonized datasets that can be
integrated with other modalities, like long-read DNA sequencing. To
date, the team has already processed 400 samples with Chromium
Single Cell Multiome and recently acquired Visium CytAssist
and Xenium In Situ instruments to explore the use of spatial
tools for the multi-region atlas.
"So much of neurodegeneration is a black box, but once you start
opening up that black box, you have many new avenues for progress.
That's what single cell analysis does; it brings to light the
ground truth of the underlying biology at massive scale and high
resolution," said Ben Hindson,
Co-founder, President and Chief Scientific Officer at 10x Genomics.
"It's energizing to see our technologies help the research
community build an expansive reference set for neuroscience, which
could ultimately lead towards developing better ways to prevent,
diagnose, treat and one day cure these devastating diseases."
The human brain atlas is intended to serve as a
neurodegenerative disease reference set that better captures
ancestral diversity to enable the translation of genetic risk to
biological consequence. The collaboration is expected to produce
high quality, standardized data that will be openly available to
the global scientific community.
NIH CARD is a collaborative initiative of the National Institute
on Aging (NIA) and National Institute of Neurological Disorders and
Stroke. This project is funded by the NIA Intramural Research
Program (ZIAAG000545). The content of this news release is solely
the responsibility of the authors and does not necessarily
represent the official views of the NIH.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with us
on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are subject
to the "safe harbor" created by those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will,""enable," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe," "see,"
"estimate," "predict," "potential," "would," "likely," "seek" or
"continue" or the negatives of these terms or variations of them or
similar terminology, but the absence of these words does not mean
that a statement is not forward-looking. These forward-looking
statements include statements regarding 10x Genomics, Inc.'s
expectations regarding the potential impacts of research conducted
using our products. These statements are based on management's
current expectations, forecasts, beliefs, assumptions and
information currently available to management, and actual outcomes
and results could differ materially from these statements due to a
number of factors. The material risks and uncertainties that could
affect 10x Genomics, Inc.'s financial and operating results and
cause actual results to differ materially from those indicated by
the forward-looking statements made in this press release include
those discussed under the captions "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" in the company's most recently-filed 10-K and elsewhere
in the documents 10x Genomics, Inc. files with the Securities and
Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. These
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures or
investments 10x Genomics, Inc. may make. Further, such
forward-looking statements may not accurately or fully reflect the
potential impact adverse events may have on the business, financial
condition, results of operations and cash flows of 10x Genomics,
Inc. The forward-looking statements in this press release are based
on information available to 10x Genomics, Inc. as of the date
hereof, and 10x Genomics, Inc. disclaims any obligation to update
any forward-looking statements provided to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics, Inc.'s views as of any
date subsequent to the date of this press release.
Disclosure Information
10x Genomics, Inc. uses filings
with the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-and-nih-card-to-create-comprehensive-single-cell-atlas-of-the-human-brain-302008212.html
SOURCE 10x Genomics, Inc